title: Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression.
abstract: BACKGROUND
  Effective intra-oesophageal acid suppression can be achieved with lansoprazole. The daily dosage could be influenced by the presence of hiatal hernia.
  
  
  OBJECTIVE
  To assess the lansoprazole daily dosage required to normalize oesophageal acid exposure in patients with and without hiatal hernia.
  
  
  METHODS
  Fifty patients with complications or atypical manifestations of gastro-oesophageal reflux disease were given lansoprazole, 30 mg once daily. Three to four weeks after the start of treatment, patients underwent oesophageal pH monitoring while on therapy. If the results were still abnormal, the lansoprazole dosage was doubled and 24-h pH-metry was repeated 20-30 days thereafter.
  
  
  RESULTS
  A 30-mg daily dosage of lansoprazole normalized oesophageal acid exposure in 70% of cases, whilst a 60-mg daily dosage was necessary in the remainder: the two groups differed only in the presence of hiatal hernia (28% vs. 100%, respectively; P=0.000). Effective intra-oesophageal acid suppression was obtained in all 25 patients without hiatal hernia with the 30-mg daily dosage of lansoprazole.
  
  
  CONCLUSIONS
  Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression in complicated and atypical gastro-oesophageal reflux disease. High efficacy of a 30-mg daily dosage of lansoprazole can be predicted in the absence of hiatal hernia.
authors.affiliation: Divisione di Medicina Interna e Gastroenterologia, Ospedale S. Agostino, Modena, Italy. marziofrazzoni@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Frazzoni
authors.forename: E
authors.initials: E
authors.lastname: De Micheli
authors.forename: A
authors.initials: A
authors.lastname: Grisendi
authors.forename: V
authors.initials: V
authors.lastname: Savarino
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005764:Gastroesophageal Reflux / Q000145:classification / Q000150:complications / Q000188:drug therapy*; D006551:Hernia, Hiatal / Q000150:complications*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D064747:Lansoprazole; D008365:Manometry; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D009853:Omeprazole